The FDA and CDC recommended a pause for Ixchiq, a chikungunya vaccine, following reports of adverse events in recipients 60 ...

The CDC began recommending Ixchiq last year for adults traveling to countries where chikungunya is common. The vaccine uses a ...

Seventy-five years of preparation for an outbreak like that of COVID-19—and yet, the Centers for Disease Control and ...

FDA Commissioner Marty Makary said his agency plans to release a new framework for vaccine approvals in “coming days.” ...

A vaccine designed to protect against chikungunya, a mosquito-borne illness, has been temporarily paused for individuals aged 60 and older.

The latest numbers from the Centers for Disease Control and Prevention show the measles outbreak has surpassed 1,000 cases ...

The CDC recommends the vaccine pause while it investigates “serious adverse events,” including neurologic and cardiac events.

The U.S. government is advising that international travelers age 60 and older not get a chikungunya vaccine as it ...

Adults over the age of 60 are recommended not to get the chikungunya vaccine to prevent the mosquito-borne illness due to two ...

Domestic and global cases have been reported to the Vaccine Adverse Event Reporting System, run by the FDA and the Centers for Disease Control and Prevention to flag potential safety problems with ...

The United States is advising travellers aged 60 and up to hold off on getting the chikungunya vaccine while it looks into ...